<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497081</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA022155-01</org_study_id>
    <secondary_id>R01DA022155</secondary_id>
    <secondary_id>1R01DA022155-01</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00497081</nct_id>
  </id_info>
  <brief_title>Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors</brief_title>
  <official_title>Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Francisco Department of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Foundation Enterprises, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>San Francisco Department of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual
      behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or
      acquiring HIV. This study of intermediate size (60 participants) and length (3 months of
      follow-up) will assess the efficacy of mirtazapine in reducing methamphetamine use among
      high-risk MSM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methamphetamine use is especially prevalent among men who have sex with men (MSM).
      Population-based surveys report methamphetamine use rates 20 times higher among MSM compared
      with the general population. Methamphetamine use is also a driving force in the MSM HIV
      epidemic: methamphetamine use has been associated with increased number of sexual partners,
      unprotected sex acts, and sexually transmitted infection (STI) and HIV acquisition. Despite
      these alarming data, relatively few interventions have been tested among
      methamphetamine-using MSM, and no studies have tested the efficacy of pharmacologic
      interventions in reducing methamphetamine use in this population. In parallel with the
      continued testing of behavioral approaches, we believe the time has come to test
      pharmacologic interventions to reduce methamphetamine use among MSM. Pharmacologic approaches
      to treating substance use have been successful in treating nicotine, alcohol, and heroin
      dependence. No studies have tested a pharmacologic intervention to reduce methamphetamine use
      among MSM at high risk for HIV acquisition and transmission. A recent pilot study found that
      mirtazapine, a drug with dual dopaminergic and serotonergic properties, significantly reduced
      methamphetamine withdrawal symptoms when compared to placebo over a two-week period among
      Thai men in a drug probation center. Mirtazapine is a commonly used, FDA-approved
      antidepressant; however, in the Thai study its effects on methamphetamine withdrawal were
      independent of its effects on depressive symptoms, suggesting a direct effect of mirtazapine
      on treating methamphetamine dependence. We propose to expand upon these promising pilot
      results by conducting a study of intermediate size (60 participants) and length (3 months of
      follow-up) to assess the efficacy of mirtazapine in reducing methamphetamine use among
      high-risk MSM.

      The specific aims of our study are:

        1. To test the hypothesis that mirtazapine 30 mg daily will reduce methamphetamine use
           significantly more than placebo among methamphetamine-dependent MSM, as determined by
           the proportion of methamphetamine-negative urines and by self-report of methamphetamine
           use in the mirtazapine versus placebo group.

        2. To measure the acceptability of mirtazapine and placebo among methamphetamine-dependent
           MSM, by determining (via electronic pill caps and self-report) medication adherence to
           mirtazapine and placebo.

        3. To measure the safety and tolerability of mirtazapine and placebo among
           methamphetamine-dependent MSM, as determined by the number of adverse clinical events in
           the mirtazapine and placebo arms.

      If promising, study results will be used to design a phase III clinical trial to determine if
      mirtazapine's effects on reducing methamphetamine use lead to reductions in
      methamphetamine-associated sexual risk. We have chosen first to conduct a 3-year
      intermediate-sized trial in order to determine if mirtazapine reduces methamphetamine use and
      whether mirtazapine demonstrates good acceptability and tolerability among a population with
      methamphetamine-associated high-risk sexual behaviors. If this proves to be the case, we
      believe our study results will provide strong support for a much larger trial to test the
      hypothesis that mirtazapine-driven reductions in methamphetamine use will result in
      corresponding decreases in sexual risk behavior. This study is therefore designed to reflect
      the structure of a larger HIV-risk reduction trial and includes both substance use and sexual
      risk behavior measures. We will enroll sexually active, methamphetamine-dependent MSM (either
      HIV-negative or HIV-positive) who will be randomized 1:1 to receive mirtazapine or placebo
      for 90 days. Because no medications have been approved to treat methamphetamine dependence,
      we include extensive safety parameters, as is required by the Food and Drug Administration
      (FDA) when testing a medication for a new indication in a new population. Participants will
      be seen weekly for urine drug testing and for brief substance use counseling. All will
      receive HIV risk-reduction counseling. Behavior will be assessed using standardized measures
      via audio computer-assisted self-interview (ACASI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number of Positive Methamphetamine Urine Tests, Comparing Baseline (Week 0) to Final Visit (Week 12).</measure>
    <time_frame>Baseline (week 0) and Final Visit (week 12)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Days With Recorded Pill Bottle Opening, as Determined by MEMS.</measure>
    <time_frame>Daily, from Baseline (week 0) through Final Visit (week 12)</time_frame>
    <description>Proportion of days with recorded pill bottle opening, as determined by MEMS (medication event monitoring system).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Adverse Events Reported</measure>
    <time_frame>From Baseline (week 0) through Final Visit (week 12)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Substance Abuse</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Mirtazapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mirtazapine 30 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 30 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirtazapine</intervention_name>
    <description>mirtazapine 30 mg daily for 3 months</description>
    <arm_group_label>Mirtazapine</arm_group_label>
    <other_name>Remeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 30 mg daily for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-negative by rapid test, or documentation of HIV infection with a laboratory result
             of a positive HIV test;

          2. male gender;

          3. reports having anal sex with men in the prior 3 months while using methamphetamine;

          4. diagnosed with methamphetamine dependence as determined by SCID;

          5. interested in stopping or reducing methamphetamine use;

          6. at least one methamphetamine-positive urine at screening and run-in period;

          7. no known allergies to mirtazapine;

          8. no current acute illnesses requiring prolonged medical care;

          9. no chronic illnesses that are likely to progress clinically during trial
             participation;

         10. able and willing to provide informed consent and to be followed over a 3-month period;

         11. age 18-60 years;

         12. baseline CBC, total protein, albumin, glucose, alk phos, creatinine, BUN and
             electrolytes without clinically significant abnormalities as determined by
             investigator in conjunction with symptoms, physical exam, and medical history.

        Exclusion Criteria:

          1. evidence of current major depression, as determined by SCID;70

          2. history of bipolar disorder or psychosis, as determined by SCID;

          3. taking anti-depressant or other psychotropic medication within the last 30 days,
             including mirtazapine or a monoamine oxidase (MAO) inhibitor;

          4. currently using or unwilling not to use pseudoephedrine-containing products for trial
             duration (causes false positive urines for methamphetamine use);

          5. current CD4 count &lt; 200 cells/mm3;

          6. measured moderate or severe liver disease (AST, ALT, and total bilirubin &gt; 3 times
             upper limit of normal) and/or any symptoms of current liver disease;

          7. impaired renal function (creatinine clearance &lt; 60 ml/min);

          8. currently participating in another research study;

          9. any condition that, in the principal investigator's judgment, interferes with safe
             study participation or adherence to study procedures.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant N Colfax, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Co-Directior, HIV Epidemiology Section, San Francisco Department of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Department of Public Health, Substance Use Research Unit</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, Shoptaw S, Vittinghoff E. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011 Nov;68(11):1168-75. doi: 10.1001/archgenpsychiatry.2011.124.</citation>
    <PMID>22065532</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2007</study_first_submitted>
  <study_first_submitted_qc>July 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <results_first_submitted>October 7, 2014</results_first_submitted>
  <results_first_submitted_qc>October 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2014</results_first_posted>
  <last_update_submitted>December 12, 2014</last_update_submitted>
  <last_update_submitted_qc>December 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Francisco Department of Public Health</investigator_affiliation>
    <investigator_full_name>Phillip Coffin, MD, MIA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine</keyword>
  <keyword>HIV</keyword>
  <keyword>MSM</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Comparator:</title>
          <description>mirtazapine 30 mg daily for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator:</title>
          <description>placebo 30 mg daily for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Comparator:</title>
          <description>mirtazapine 30 mg daily for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo Comparator:</title>
          <description>placebo 30 mg daily for 3 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="8.0"/>
                    <measurement group_id="B2" value="40.1" spread="10.1"/>
                    <measurement group_id="B3" value="40.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" spread="60"/>
                    <measurement group_id="B2" value="19" spread="63"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" spread="20"/>
                    <measurement group_id="B2" value="5" spread="17"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="10"/>
                    <measurement group_id="B2" value="4" spread="13"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="10"/>
                    <measurement group_id="B2" value="2" spread="7"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Positive Methamphetamine Urine Tests, Comparing Baseline (Week 0) to Final Visit (Week 12).</title>
        <time_frame>Baseline (week 0) and Final Visit (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator:</title>
            <description>mirtazapine 30 mg daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator:</title>
            <description>placebo 30 mg daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Positive Methamphetamine Urine Tests, Comparing Baseline (Week 0) to Final Visit (Week 12).</title>
          <units>Percentage reduction</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Days With Recorded Pill Bottle Opening, as Determined by MEMS.</title>
        <description>Proportion of days with recorded pill bottle opening, as determined by MEMS (medication event monitoring system).</description>
        <time_frame>Daily, from Baseline (week 0) through Final Visit (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator:</title>
            <description>mirtazapine 30 mg daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator:</title>
            <description>placebo 30 mg daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Days With Recorded Pill Bottle Opening, as Determined by MEMS.</title>
          <description>Proportion of days with recorded pill bottle opening, as determined by MEMS (medication event monitoring system).</description>
          <units>Percentage of recorded openings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="26.9"/>
                    <measurement group_id="O2" value="48.7" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Adverse Events Reported</title>
        <time_frame>From Baseline (week 0) through Final Visit (week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator:</title>
            <description>mirtazapine 30 mg daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator:</title>
            <description>placebo 30 mg daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events Reported</title>
          <units>Adverse Events Reported</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Comparator:</title>
          <description>mirtazapine 30 mg daily for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator:</title>
          <description>placebo 30 mg daily for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression (spine)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Meth-induced Psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased ALT</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased AST</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gonorrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Skin and Soft Tissue Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Glenn-Milo Santos, MPH</name_or_title>
      <organization>San Francisco Department of Public Health</organization>
      <phone>415.437.6231</phone>
      <email>glenn-milo.santos@sfdph.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

